Patent intelligence · US
US 2002161051
(2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
(2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
Patent details — US 2002161051
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 31, 2002
- Expiration
- Oct 26, 2022
- Applicant
- ALLERGAN INC [US]
- CPC classes
- A61K31/17, A61K31/215, A61K31/22, A61K31/225
Quick answer
US 2002161051 ((2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors) is held by ALLERGAN INC [US]. Status: expired. Granted Oct 31, 2002. Expires Oct 26, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K31/17, A61K31/215, A61K31/22, A61K31/225, A61P 29/ 00 A I, A61P/2900
More from ALLERGAN INC [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2002161051?
US 2002161051 ((2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors) is held by ALLERGAN INC [US]. Status: expired. Granted Oct 31, 2002. Expires Oct 26, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2002161051?
ALLERGAN INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 2002161051 expire?
Our index shows an expiration date of Oct 26, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.